Intestinal Biomarker Detection for Poultry Gut Health
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing intestinal health in poultry are invasive, subjective, and lack specific biomarkers for gut damage, making it difficult to monitor subclinical intestinal entities that affect performance.
Innovation Solution
A non-invasive method using a set of proteins (myeloid protein 1, fibronectin, annexin A5, nucleophosmin, carbonic anhydrase 2, aminopeptidase Ey, transthyretin, ovoinhibitor, and apolipoprotein A-1) quantified in intestinal content samples to assess gut health, correlating with markers such as villi shortening and inflammation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If macroscopic observations of the intestinal wall are used to monitor intestinal lesions, then the monitoring can be easily performed, but the detection precision is insufficient for subtle intestinal pathologies
Solution Approach 1:
The patent introduces intestinal content samples as an intermediary medium that contains biomarkers reflecting intestinal health status. These biomarkers serve as mediators between the intestinal wall condition and the detection method, allowing indirect but precise monitoring of intestinal pathology through quantifiable molecular markers in the intestinal content
Solution Approach 2:
The patent replaces subjective macroscopic visual observation with objective quantitative biomarker measurement. Instead of relying on visual assessment of intestinal wall appearance, the method uses biochemical analysis of specific proteins and metabolites in intestinal content, substituting mechanical/visual inspection with molecular-level detection
2Measurement precision
If histopathological microscopic observations are performed to obtain accurate picture of intestinal health, then the measurement precision is improved, but the method complexity and time consumption increase
Solution Approach 1:
The patent extracts specific biomarkers from the complex intestinal tissue and focuses measurement on these isolated molecular markers rather than performing comprehensive histopathological examination. By taking out and measuring only the relevant biomarkers (such as specific proteins, metabolites) in intestinal content, the method achieves precise intestinal health assessment without the complexity of full histological analysis
Solution Approach 2:
The patent changes the measurement parameter from macroscopic visual characteristics or microscopic tissue structure to molecular-level biomarker concentrations. By shifting from structural parameters (villus height, crypt depth) to biochemical parameters (protein levels, metabolite concentrations), the method achieves comparable or superior precision with simplified procedures
3Measurement precision
If post-mortem intestinal health monitoring is performed using traditional methods, then the diagnostic accuracy is achieved, but the predictive value for living animals is limited
Solution Approach 1:
The patent enables preliminary detection of intestinal health status by measuring biomarkers in intestinal content from living animals before clinical symptoms develop. By detecting changes in biomarker levels (such as increased permeability markers, inflammatory proteins) in the intestinal content, the method provides early warning of impending intestinal damage, allowing preventive intervention before the disease manifests
4Measurement precision
If invasive blood sampling is used to measure intestinal biomarkers, then the measurement precision is improved, but the ease of operation decreases
Solution Approach 1:
The patent uses intestinal content samples as a non-invasive copy or proxy for intestinal tissue analysis. Instead of directly sampling blood or tissue, the method analyzes biomarkers present in the intestinal content (feces, luminal fluid) which reflect the intestinal health status. This copying approach provides equivalent diagnostic information without the invasiveness of blood sampling
Data Source
Figure 1a
Figure 1b
Figure 1c
AI summary
Growth performance, health and welfare of domesticated birds such as broilers heavily depends on a well-functioning intestinal tract. Consequently, there is a high need to find biomarkers which are specific for gut damage and which are easily applicable in the field. The present invention discloses a set of 20 specific proteins which can be quantified in fresh fecal droppings and/or intestinal content of said birds and which each specifically correlate with a damaged gut.